Next Article in Journal
Novel 7-Chloro-(4-thioalkylquinoline) Derivatives: Synthesis and Antiproliferative Activity through Inducing Apoptosis and DNA/RNA Damage
Next Article in Special Issue
Agathis robusta Bark Extract Protects from Renal Ischemia-Reperfusion Injury: Phytochemical, In Silico and In Vivo Studies
Previous Article in Journal
Effects of Myristicin in Association with Chemotherapies on the Reversal of the Multidrug Resistance (MDR) Mechanism in Cancer
Previous Article in Special Issue
Xylan Prebiotics and the Gut Microbiome Promote Health and Wellbeing: Potential Novel Roles for Pentosan Polysulfate
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceuticals
Volume 15
Issue 10
10.3390/ph15101231
pharmaceuticals-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Systematic Review

Unravelling Potential Health-Beneficial Properties of Corema album Phenolic Compounds: A Systematic Review

by
Ana Sofia Cerquido
1,
Martin Vojtek
1,
Rita Ribeiro-Oliveira
1,
Olga Viegas
2,3,
Joana Beatriz Sousa
1,*,
Isabel M. P. L. V. O. Ferreira
2,* and
Carmen Diniz
1,*
1
LAQV/REQUIMTE, Laboratory of Pharmacology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal
2
LAQV/REQUIMTE, Laboratory of Bromatology and Hydrology, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal
3
Faculty of Nutrition and Food Sciences, University of Porto, 4150-180 Porto, Portugal
*
Authors to whom correspondence should be addressed.
Pharmaceuticals 2022, 15(10), 1231; https://doi.org/10.3390/ph15101231
Submission received: 7 September 2022 / Revised: 26 September 2022 / Accepted: 27 September 2022 / Published: 8 October 2022
(This article belongs to the Special Issue Natural Pharmacons: Biologically Active Plant-Based Pharmaceuticals 2022)
Browse Figures
Versions Notes

Abstract

:
Corema (C.) album belongs to the family Ericaceae and can be found in the Iberian Peninsula, especially on the coastal areas facing the Atlantic coast. C. album berries have been used for centuries in traditional medicine. Recent studies have revealed that not only the berries but also the leaves have relevant antioxidant, antiproliferative, and anti-inflammatory properties, bringing this plant to the forefront of discussion. A systematic review of the literature was carried out to summarize the phenolic compounds and bioactive properties identified in C. album berries and leaves and to search for research gaps on this topic. The search was conducted in three electronic databases (PubMed, SCOPUS, and Web of Science) using PRISMA methodology. The inclusion criteria were the chemical compositions of the berries, leaves, or their extracts and their bioactive properties. The exclusion criteria were agronomic and archaeological research. The number of studies concerning phenolic compounds’ composition and the bioactive properties of C. album berries and leaves is still limited (11 articles). However, the variety of polyphenolic compounds identified make it possible to infer new insights into their putative mechanism of action towards the suppression of NF-kB transcription factor activation, the modulation of inflammatory mediators/enzymes, the induction of apoptosis, the modulation of mitogen activated protein kinase, cell cycle arrest, and the reduction of oxidative stress. These factors can be of major relevance concerning the future use of C. album as nutraceuticals, food supplements, or medicines. Nevertheless, more scientific evidence concerning C. album’s bioactivity is required.

1. Introduction

Plants as natural medicinal agents have been used since ancient civilizations to treat diseases such as cancer, inflammation, fever, etc. Their value as sources of molecules with therapeutic potential has been recognized and, recently, they have gained much attention in the drug discovery field, since many drugs from natural sources have been emerging, currently constituting up to 50% of all drugs in the pharmaceutical industry [1].
Corema belongs to the family Ericaceae and includes two species: Corema conradii and Corema album. The first is native to the Northwest coast of the USA and the latter can be found in the Iberian Peninsula, especially on the coastal areas facing the Atlantic [2]. In addition, Corema conradii differs from Corema album mainly by its very small fruit that lacks fleshiness and is covered with oily appendages [3]. Both species are coastal shrubs with sexual dimorphism. Concerning Corema album, this plant is a densely branched and long-living shrub with evergreen leaves [4]. While male flowers are bigger and have reddish petals and stamens with red-purple anthers, female flowers are smaller with pink-reddish petals [5]. Traditionally, the plant itself was also used in the Iberian Peninsula to make rustic brooms [6].
The berries from Corema album have been consumed for many centuries since the Islamic period (either fresh or in jams) and are employed in popular medicine [6,7]. In recent years, several reports have highlighted the health-beneficial properties of Corema album against several diseases, including cancer and neurodegenerative and cardiovascular diseases, and have ascribed most of their beneficial effects to their composition of phenolic compounds. Thus, this review is focused on unravelling the phenolic compounds already identified in Corema album with an emphasis on describing the biological mechanisms and signalling pathways related to their health-beneficial properties.
The species Corema album has two subspecies: Corema album azoricum, which is native to the islands of Azores, and Corema album album (C. album), which is more commonly found on the mainland [2]. The main difference between these two subspecies resides in its area of distribution: Corema album azoricum typically grows on volcanic lava or ash fields whereas C. album is characteristically found in coastal habitats [4].
C. album is an evergreen wild shrub that grows mainly on sandy soil over coastal dunes and cliffs, reaching a maximum height of 1 m, with numerous branches exhibiting leaves. Along the coast of Portugal, C. album is predominant on the southwest region from Sines to Troia and in the central-north region from Nazaré to Ovar [6]. The flowering of both female and male plants begins in early spring, from February to April [4]. The fruits are produced by the female plants and ripen in early summer (June and July) in the south and a little later (August and September) in the north [6]. The fruits are small, round berries coloured white or pink-white when ripe with an acidic flavour [8].
C. album has been used in traditional medicine and is one of the medicinal plants included in the herbarium of Francesc Bolòs (1773–1844) [9]. It has been described to exhibit beneficial properties against fever and intestinal pinworm infection [6,7], which is in accordance with the reported ability of C. album extracts to prevent oxidative damage [7]. Recently, the composition of each part of C. album has been studied by complementary Raman and infrared techniques, revealing vibrational signatures for the skin (outer and inner) and the seeds with distinct chemical compositions, specifically in its respective content in phenolic derivatives [10,11]. A systematic review of the literature was carried out to summarize the phenolic compounds and bioactive properties identified in C. album berries and leaves and to search for research gaps in this topic.

2. Methods

2.1. Search Strategy

PRISMA methodology was applied by performing a search for publications in three databases, namely, PubMed, SCOPUS, and Web of Science, using the following keywords: (“Corema album” AND (berries OR leaves)). The collection of papers was performed up to 15 June 2022. A total of 74 publications were identified after compiling all three databases. Duplicates, reviews, and opinion articles (n = 40) were removed.

2.2. Inclusion and Exclusion Criteria

The two authors of this publication independently screened the titles and abstracts of the 34 remaining articles. Inclusion criteria were studies focusing on chemical composition of berries, leaves, or their extracts and their bioactive properties. Exclusion criteria were agronomic and archaeological studies. Then, the full texts of eligible articles were carefully studied by all authors and the relevant data concerning phenolic compounds identified, C. album samples (berries, leaves, and extracts), and the bioactive properties studied were collected. In all steps, disagreements were resolved by meeting all authors and deciding on the inclusion or exclusion of the articles together.

3. Results

3.1. Literature Search Process

From the 74 records identified, only 34 remained for the title and abstract screening. The remaining reports were duplicated articles, reviews, or opinion articles (Figure 1). Then, 21 articles were excluded based on the title and abstract reviews because these studies involved agronomic or archaeological studies and did not include the chemical composition of the berries, leaves, or of the respective extracts. The remaining 13 papers proceeded to the full text review. From those, only 11 were about phenolic compounds’ identification in C. album; thus, they were considered eligible for the data extraction [7,10,11,12,13,14,15,16,17,18,19].

3.2. Phenolic Compounds in Berries and Leaves from C. album

Both berries and leaves from C. album revealed a rich content in several phenolic compounds, which are summarized in Table 1 and Table 2, respectively. The phenolic compounds were divided into three main groups, namely, phenolic acids, flavonoids, and stilbenes, according to their structural similarities. Phenolic acids are commonly divided into two groups: the benzoic acids (C6-C1) with seven carbon atoms and cinnamic acids (C6-C3) with nine carbon atoms. Usually, these compounds occur predominantly in their hydroxylated forms: hydroxybenzoic and cinnamic acids, respectively. Flavonoids present a basic structure with 15 carbon atoms distributed by two aromatic rings linked by a three-carbon chain (C6-C3-C6). Stilbenes are known to display a structure with two aromatic rings linked by an ethene bridge.
Moreover, and in accordance with previously described features [20], natural phenolic acids, free or conjugated, can also appear as amides or esters whereas natural flavonoids, free or conjugated, are often esterified to one or two sugar molecules (by one or more hydroxyl groups).
In C. album leaves, another three predominant compounds were identified: 2′,4′-dihydroxydihydrochalcone, 2′-methoxy-4′-hydroxydihydrochalcone [17], and 2′,4′-dihydroxychalcone [18] (Figure 2). These compounds are chalcones, which are intermediates in the biosynthesis of flavonoids and isoflavonoids [19].
Both the berries and leaves from C. album revealed interesting bioactive properties, which are summarized in Figure 3. Scientific information regarding C. album’s bioactive activities is very scarce and is mostly focused on the beneficial healthy properties of its berries. C. album berries were described to have antimicrobial [11] and antioxidant activities [7,11,14,15]. Moreover, this antioxidant activity seems to be increased after simulated digestion [13] and can protect against oxidative stress (yeast: [13]). C. album berries have also been described as having cytotoxic effects in Caco-2 cells when the concentration of the extract exceeds 8% [14]. There is also evidence that these berries are able to inhibit lipid peroxidation and acetylcholinesterase activation [11].
The bioactivity of C. album leaves has been studied regarding its cytotoxicity in yeast [15,20]; colon carcinoma cells (HT-29 cells: [17]), an effect that seems to be mediated through G2/M cell cycle arrest [18,21]; and apoptosis [18]. The cytotoxicity observed was reported to be triggered by the pro-oxidant activity of at least two different hydroxydihydrochalcones found in these leaves [17]. In contrast, a study using an enriched fraction of polyphenols from C. album leaves claimed that this extract has promising cytoprotective effects, modulating key events in Parkinson’s disease pathogenesis. Some other reports also describe C. album leaves as having antioxidant effects [15,20].

4. Discussion

A wide variety of phenolic compounds were identified in the berries and leaves from C. album, but few studies explore the biological activities and signalling events triggered by their extracts. Nevertheless, their physical–chemical profile and high phenolic content supports a potential market expansion [22]. In particular, their enriched composition in phenolic compounds, both in the berries and leaves, bring valuable insights into their putative mechanism of action. Currently, it is well accepted that phenolic compounds can modulate the activity of several enzymes, kinases, and transcriptional factors involved in the modulation of biological processes such as oxidative stress, inflammation, cell proliferation, apoptosis, and cell death [21,23]. In accordance, the phenolic compounds previously identified in C. album berries and leaves are known to present a modulatory capability in several signalling pathways, signal mediators or enzymes, and/or kinases (Table 3 and Table 4). Thus, these mechanisms can be indirectly associated with C. album.
Note that the phenolic compounds may exert their biological effects through signalling pathways separately or in a sequential way. Moreover, a putative crosstalk between these pathways should not be overlooked.

4.1. Suppression of NF-kB Transcription Factor Activation

The nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-κB) is a transcription factor involved in the regulation of the expression of several genes that are associated with inflammation and carcinogenesis. NF-κB, in the cytosol, is inactive since it is bound to inhibitor kB (IkB) [83]. When IκB is phosphorylated, NF-κB is free to be translocated to the nucleus and can activate genes such as p53, Myc, and other cellular genes [21,83]. Present in C. album berries, neochlorogenic [37,39,40], p-hydroxybenzoic [24], and ferulic [28,29] acids seem to be able to inhibit NF-κB activation. In addition, several flavonols such as catechins [66,67,68,69], quercetin rhamnosyl hexoside [78,79,80], myricetin [74,75], procyanidins [72,73] and kaempherol hexoside [76], identified in C. album leaves have been shown to suppress NF-κB transcriptional activity and, thus, can prevent inflammation and carcinogenesis.

4.2. Modulation of Inflammatory Mediators/Enzymes

All the phenolic acids identified in C. album berries present anti-inflammatory properties since they inhibit the production of several interleukins (IL-1β and IL-6) and TNF-α (Table 3). The following activities were reported in the leaves of C. album: some polyphenols, such as catechins, were shown to inhibit IL-6, IL-12, and IL-1α; IL-1β, TNF-α production [67,68]; procyanidins, shown to inhibit IL-1β and TNF-α expression [72]; quercetin rhamnosyl hexoside, which decreased the expression of TNF-α, IL-1β, IL-6, and IL-17 [78,81,82]; kaempherol hexoside, which suppressed TNF-α, IL-1β, and IL-6 generation [77]; myricetin, which reduced TNF-α, IL-12, and IL-6 expression [74]; and rhamnetin, which reduced TNF-α, IL-1β, IL-6, and IL-8 generation [84]. In addition, other compounds were identified in the leaves such as chalcone derivatives that inhibited the production of cytokines [85]; isoliquiritigenin and butein that inhibited lipopolysaccharide (LPS)-induced inducible nitric oxide synthase (iNOS); and cyclooxygenase-2 (COX-2) expression [86], contributing to the modulation of inflammation.
In the inflammatory process, enzymes such as COX-2 and xanthine oxidase (XO) play a key role, and their levels of expression are modulated during the inflammation’s progression. The polyphenols identified in the berries of C. album were shown to be capable of suppressing/reducing the activity of XO and/or COX-2: through phenolic acids such as chlorogenic [37] or p-hydroxybenzoic [24] acids or by flavonols such as quercetin-3-O-hexoside [48].

4.3. Induction of Apoptosis

Apoptotic regulation involves numerous proteins such as families of p53, bcl-2-like protein 4 (BAX), and caspases [23]. Several flavonols identified in C. album berries seem to be able to induce apoptosis: anthocyanins, such as delphinidin-3-O-hexoside can induce apoptosis by modifying BAX, caspase 3, and Bcl-2 proteins [64]; quercetin-3-O-hexoside seems to be able to promote apoptosis, enhancing the expression of p53 and BAX proteins [46]; and kaempherol-3-O-hexoside was associated with the induction of apoptosis through the upregulation of caspase 3 and the downregulation of Bcl-2 [41,43,44]. Another flavonoid identified in C. album leaves, pinocembrin, was reported to be able to induce apoptosis in many different types of cancer cells [87].

4.4. Modulation of Mitogen Activated Protein Kinase

Since mitogen-activated protein kinase (MAPK) pathways are a convergent avenue involved in numerous biological processes, changes in MAPK activity are of utmost importance. p-coumaric acid has been demonstrated to have both antioxidant and anti-inflammatory properties since it is capable of preventing oxidative stress-induced apoptosis in human epithelial cells through the modulation of the MAPK signalling pathway [88]. Other phenolic acids identified in C. album berries, such as ferulic acid [28,29], p-hydroxybenzoic acid [24], and neochlorogenic acid [36,40], can also prevent MAPK activation. In the leaves, some polyphenols have also been reported to exert modulatory effects on MAPK pathways, including quercetin rhamnosyl hexoside [79] and procyanidins [73].

4.5. Cell Cycle Arrest

The deregulation of the cell cycle is associated with carcinogenesis and phenolic compounds are known to be capable of inhibiting, in a variety of cell types, different cell phases (G1, S, S/G2, and G2) [21,89]. C. album flavonols, identified in the berries, are capable of changing the cell cycle; kaempherol-O-hexoside causes cell cycle arrest at G2 [43,45] while rutin (a quercetin derivative) induces G2/M cell cycle arrest [54].

4.6. Zeduction of Oxidative Stress

The antioxidant properties ascribed to C. album seem to be mediated by an upregulation of glutathione and cellularly antioxidant enzymes, as well as by the suppression of reactive oxygen species (ROS) generation [90,91]. Indeed, berries usually exhibit an enriched content of phenolic compounds commonly associated with their high antioxidant properties [15]. Such properties are also exhibited by C. album berries since they have an anthocyanin content that can inhibit the intracellular content of ROS [63,64,65]. In these berries, gallic acid, chlorogenic acid derivatives, and flavonols have also been identified as having antioxidant properties [15,24,51,53].
Some compounds identified in the leaves of C. album also have antioxidant properties: myricetin derivatives [74,75], reported as a modulator of nitric oxide (NO) generation and of iNOS activity; stilbene derivatives [92]; and prenylated chalcone glycoside, which showed radical scavenging activity [93].

5. Conclusions and Future Perspectives

Although a wide variety of phenolic compounds have been identified in the berries and leaves from C. album, at the time of this review (15th Jun 2022), there are scarce scientific data regarding the potential health benefits exerted by C. album. Only nine studies have evaluated the biological properties of the berries, leaves, or respective extracts of this plant. Nevertheless, the discussion section evidences that their rich composition in phenolic compounds is promising when considering their health benefits and therapeutic potential. The phenolic compounds identified in C. album leaves and berries can modulate several pathophysiological processes, namely, inflammation, oxidative stress, carcinogenesis, etc., and this plant may also be attractive to the pharmaceutical industry with respect to generating new drug(s), nutraceuticals, or supplements, but more scientific evidence concerning C. album’s bioactivity is required.

Author Contributions

Conceptualization: C.D., M.V., R.R.-O. and J.B.S.; writing—original draft preparation, C.D., M.V., A.S.C. and O.V.; writing—review and editing, C.D., M.V., J.B.S., A.S.C., R.R.-O. and I.M.P.L.V.O.F.; funding acquisition, I.M.P.L.V.O.F. and C.D. All authors have read and agreed to the published version of the manuscript.

Funding

The Portuguese Foundation for Science and Technology (FCT) is acknowledged for UIDB/QUI/50006/2020, and Portugal 2020—POCI-01-0145-FEDER-029305, IDEAS4life—Novos IngreDiEntes Alimentares de Plantas MarítimaS (jointly financed by the European Community Fund and FEDER).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data sharing not applicable.

Acknowledgments

Martin Vojtek thanks the Portuguese Foundation for Science and Technology (FCT) and the PhD Program in Medicines and Pharmaceutical Innovation (i3DU) for PhD Grant PD/BD/135460/2017, funded by the European Social Fund of the European Union and national funds FCT/MCTES. Rita Ribeiro–Oliveira thanks the Portuguese Foundation for Science and Technology (FCT) for PhD Grant SFRH/BD/146243/2019 funded by the European Social Fund of the European Union and national funds FCT/MCTES through the Norte’s Regional Operational Programme. The authors thank Maria do Céu Pereira e Mónica Caldas for their technical assistance.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Newman, D.J.; Cragg, G.M. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J. Nat. Prod. 2012, 75, 311–335. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Andrade, S.C.; Gonçalves, F.; Guiné, R. Contribution for the physical-chemical characterization of Portuguese Crowberry (Corema album). Int. J. Food Sci. Nutr. 2017, 2, 9–14. [Google Scholar]
  3. Martine, C.T.; Lubertazzi, D.; Dubrul, A. The biology of Corema conradii: Natural history, reproduction, and observations of a post-fire seedling recruitment. Northeast. Nat. 2005, 12, 267–286. [Google Scholar] [CrossRef]
  4. Guitián, P.; Medrano, M.; Rodríguez, M. Reproductive biology of Corema album (L.) D. Don (Empetraceae) in the northwest Iberian Peninsula. Acta Bot. Gall. 1997, 144, 119–128. [Google Scholar] [CrossRef] [Green Version]
  5. Zunzunegui, M.; Barradas, M.D.; Clavijo, A.; Cansino, L.A.; Lhout, F.A.; Novo, F.G. Ecophysiology, growth timing and reproductive effort of three sexual foms of Corema album (Empetraceae). Plant Ecol. 2006, 183, 35–46. [Google Scholar] [CrossRef]
  6. de Oliveira, P.B.; Dale, A. Corema album (L.) D. Don, the white crowberry—A new crop. J. Berry Res. 2012, 2, 123–133. [Google Scholar] [CrossRef] [Green Version]
  7. León-González, A.J.; Mateos, R.; Ramos, S.; Martín, M.Á.; Sarriá, B.; Martín-Cordero, C.; López-Lázaro, M.; Bravo, L.; Goya, L. Chemo-protective activity and characterization of phenolic extracts from Corema album. Food Res. Int. 2012, 49, 728–738. [Google Scholar] [CrossRef] [Green Version]
  8. López-Dóriga, I.L. The archaeobotany and ethnobotany of Portuguese or white crowberry (Corema album (L.) D. Don). Ethnobiol. Lett. 2018, 9, 19–32. [Google Scholar] [CrossRef]
  9. Gras, A.; Garnatje, T.; Ibáñez, N.; López-Pujol, J.; Nualart, N.; Vallès, J. Medicinal plant uses and names from the herbarium of Francesc Bolòs (1773-1844). J. Ethnopharmacol 2017, 204, 142–168. [Google Scholar] [CrossRef] [Green Version]
  10. Martin, D.; Marques, J.; Amado, A.M.; Barroca, M.J.; Moreira da Silva, A.; Batista de Carvalho, L.A.E.; Marques, M.P.M. Shedding light into the health-beneficial properties of Corema album—A vibrational spectroscopy study. J. Raman Spectrosc. 2020, 51, 313–322. [Google Scholar] [CrossRef]
  11. Marques, J.; Martin, D.; Amado, A.M.; Lysenko, V.; Osório, N.; Batista de Carvalho, L.A.E.; Marques, M.P.M.; Barroca, M.J.; Moreira da Silva, A. Novel Insights into Corema album Berries: Vibrational Profile and Biological Activity. Plants 2021, 10, 1761. [Google Scholar] [CrossRef] [PubMed]
  12. León-González, A.J.; Truchado, P.; Tomás-Barberán, F.A.; López-Lázaro, M.; Barradas, M.C.D.; Martín-Cordero, C. Phenolic acids, flavonols and anthocyanins in Corema album (L.) D. Don berries. J. Food Compos. Anal. 2013, 29, 58–63. [Google Scholar] [CrossRef]
  13. Andrade, S.C.; Guiné, R.P.F.; Gonçalves, F.J.A. Evaluation of phenolic compounds, antioxidant activity and bioaccessibility in white crowberry (Corema album). J. Food Meas. Charact. 2017, 11, 1936–1946. [Google Scholar] [CrossRef]
  14. Brito, C.; Bertotti, T.; Primitivo, M.J.; Neves, M.; Pires, C.L.; Cruz, P.F.; Martins, P.A.T.; Rodrigues, A.C.; Moreno, M.J.; Brito, R.M.M.; et al. Corema album spp: Edible wild crowberries with a high content in minerals and organic acids. Food Chem. 2021, 345, 128732. [Google Scholar] [CrossRef] [PubMed]
  15. Macedo, D.; Tavares, L.; McDougall, G.J.; Vicente Miranda, H.; Stewart, D.; Ferreira, R.B.; Tenreiro, S.; Outeiro, T.F.; Santos, C.N. (Poly)phenols protect from α-synuclein toxicity by reducing oxidative stress and promoting autophagy. Hum. Mol. Genet. 2015, 24, 1717–1732. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  16. Jardim, C.; Macedo, D.; Figueira, I.; Dobson, G.; McDougall, G.J.; Stewart, D.; Ferreira, R.B.; Menezes, R.; Santos, C.N. (Poly)phenol metabolites from Arbutus unedo leaves protect yeast from oxidative injury by activation of antioxidant and protein clearance pathways. J. Funct. Foods 2017, 32, 333–346. [Google Scholar] [CrossRef]
  17. León-González, A.J.; López-Lázaro, M.; Espartero, J.L.; Martín-Cordero, C. Cytotoxic Activity of Dihydrochalcones Isolated from Corema Album Leaves against HT-29 Colon Cancer Cells. Nat. Prod. Commun. 2013, 8, 1934578X1300800. [Google Scholar] [CrossRef] [Green Version]
  18. Leon-Gonzalez, A.J.; Manson, M.M.; Lopez-Lazaro, M.; Navarro, I.; Martin-Cordero, C. Induction of apoptosis and cell cycle arrest in human colon carcinoma cells by corema album leaves. Nat. Prod. Commun. 2014, 9, 1934578X1400900117. [Google Scholar] [CrossRef] [Green Version]
  19. Wong, E. The role of chalcones and flavanones in flavonoid biosynthesis. Phytochemistry 1968, 7, 1751–1758. [Google Scholar] [CrossRef]
  20. Sánchez-Picó, Á.; León-González, A.J.; Martín-Cordero, C.; Daga, R.R. Screening for natural anticancer agents using a fission yeast bioassay. Phytochem. Lett. 2014, 8, 184–189. [Google Scholar] [CrossRef]
  21. Fresco, P.; Borges, F.; Diniz, C.; Marques, M. New insights on the anticancer properties of dietary polyphenols. Med. Res. Rev. 2006, 26, 747–766. [Google Scholar] [CrossRef]
  22. Jacinto, J.; Giovanetti, M.; Oliveira, P.B.; Valdiviesso, T.; Máguas, C.; Alegria, C. Quality attributes of cultivated white crowberries (Corema album (L.) D. Don) from a multi-origin clonal field. Euphytica 2021, 217, 40. [Google Scholar] [CrossRef]
  23. Fresco, P.; Borges, F.; Marques, M.P.; Diniz, C. The anticancer properties of dietary polyphenols and its relation with apoptosis. Curr. Pharm. Des. 2010, 16, 114–134. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Lee, J.; Ha, S.J.; Lee, H.J.; Kim, M.J.; Kim, J.H.; Kim, Y.T.; Song, K.M.; Kim, Y.J.; Kim, H.K.; Jung, S.K. Protective effect of Tremella fuciformis Berk extract on LPS-induced acute inflammation via inhibition of the NF-κB and MAPK pathways. Food Funct. 2016, 7, 3263–3272. [Google Scholar] [CrossRef] [PubMed]
  25. Peng, J.; Zheng, T.; Liang, Y.; Duan, L.; Zhang, Y.; Wang, L.-J.; He, G.; Xiao, H. P-Coumaric Acid Protects Human Lens Epithelial Cells Against Oxidative Stress-Induced Apoptosis by MAPK signaling. Oxidative Med. Cell. Longev. 2018, 2018, 8549052. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  26. Zhu, H.; Liang, Q.H.; Xiong, X.G.; Wang, Y.; Zhang, Z.H.; Sun, M.J.; Lu, X.; Wu, D. Anti-Inflammatory Effects of p-Coumaric Acid, a Natural Compound of Oldenlandia diffusa, on Arthritis Model Rats. Evid. Based Complement. Altern. Med. 2018, 2018, 5198594. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  27. Prasad, N.R.; Ramachandran, S.; Pugalendi, K.V.; Menon, V.P. Ferulic acid inhibits UV-B–induced oxidative stress in human lymphocytes. Nutr. Res. 2007, 27, 559–564. [Google Scholar] [CrossRef]
  28. Yin, P.; Zhang, Z.; Li, J.; Shi, Y.; Jin, N.; Zou, W.; Gao, Q.; Wang, W.; Liu, F. Ferulic acid inhibits bovine endometrial epithelial cells against LPS-induced inflammation via suppressing NK-κB and MAPK pathway. Res. Vet. Sci. 2019, 126, 164–169. [Google Scholar] [CrossRef]
  29. Cao, Y.; Zhang, Y.; Qi, J.; Liu, R.; Zhang, H.; He, L. Ferulic acid inhibits H2O2-induced oxidative stress and inflammation in rat vascular smooth muscle cells via inhibition of the NADPH oxidase and NF-κB pathway. Int. Immunopharmacol. 2015, 28, 1018–1025. [Google Scholar] [CrossRef]
  30. Zhang, M.; Zhou, J.; Wang, L.; Li, B.; Guo, J.; Guan, X.; Han, Q.; Zhang, H. Caffeic acid reduces cutaneous tumor necrosis factor alpha (TNF-alpha), IL-6 and IL-1beta levels and ameliorates skin edema in acute and chronic model of cutaneous inflammation in mice. Biol. Pharm. Bull. 2014, 37, 347–354. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  31. Prasad, N.R.; Karthikeyan, A.; Karthikeyan, S.; Reddy, B.V.J.M.; Biochemistry, C. Inhibitory effect of caffeic acid on cancer cell proliferation by oxidative mechanism in human HT-1080 fibrosarcoma cell line. Mol. Cell. Biochem. 2011, 349, 11–19. [Google Scholar] [CrossRef]
  32. Shan, J.; Fu, J.; Zhao, Z.; Kong, X.; Huang, H.; Luo, L.; Yin, Z. Chlorogenic acid inhibits lipopolysaccharide-induced cyclooxygenase-2 expression in RAW264.7 cells through suppressing NF-kappaB and JNK/AP-1 activation. Int. Immunopharmacol. 2009, 9, 1042–1048. [Google Scholar] [CrossRef] [PubMed]
  33. Zheng, Z.; Sheng, Y.; Lu, B.; Ji, L. The therapeutic detoxification of chlorogenic acid against acetaminophen-induced liver injury by ameliorating hepatic inflammation. Chem. Biol. Interact. 2015, 238, 93–101. [Google Scholar] [CrossRef] [PubMed]
  34. Kang, T.Y.; Yang, H.R.; Zhang, J.; Li, D.; Lin, J.; Wang, L.; Xu, X. The studies of chlorogenic Acid antitumor mechanism by gene chip detection: The immune pathway gene expression. J. Anal. Methods Chem. 2013, 2013, 617243. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  35. Búfalo, M.C.; Ferreira, I.; Costa, G.; Francisco, V.; Liberal, J.; Cruz, M.T.; Lopes, M.C.; Batista, M.T.; Sforcin, J.M. Propolis and its constituent caffeic acid suppress LPS-stimulated pro-inflammatory response by blocking NF-κB and MAPK activation in macrophages. J. Ethnopharmacol. 2013, 149, 84–92. [Google Scholar] [CrossRef]
  36. Yun, N.; Kang, J.W.; Lee, S.M. Protective effects of chlorogenic acid against ischemia/reperfusion injury in rat liver: Molecular evidence of its antioxidant and anti-inflammatory properties. J. Nutr. Biochem. 2012, 23, 1249–1255. [Google Scholar] [CrossRef]
  37. Gao, X.H.; Zhang, S.D.; Wang, L.T.; Yu, L.; Zhao, X.L.; Ni, H.Y.; Wang, Y.Q.; Wang, J.D.; Shan, C.H.; Fu, Y.J. Anti-Inflammatory Effects of Neochlorogenic Acid Extract from Mulberry Leaf (Morus alba L.) Against LPS-Stimulated Inflammatory Response through Mediating the AMPK/Nrf2 Signaling Pathway in A549 Cells. Molecules 2020, 25, 1385. [Google Scholar] [CrossRef] [Green Version]
  38. Kim, M.; Choi, S.Y.; Lee, P.; Hur, J. Neochlorogenic Acid Inhibits Lipopolysaccharide-Induced Activation and Pro-inflammatory Responses in BV2 Microglial Cells. Neurochem. Res. 2015, 40, 1792–1798. [Google Scholar] [CrossRef]
  39. Chang, C.H.; Chang, Y.T.; Tseng, T.H.; Wang, C.J. Mulberry leaf extract inhibit hepatocellular carcinoma cell proliferation via depressing IL-6 and TNF-alpha derived from adipocyte. J. Food Drug Anal. 2018, 26, 1024–1032. [Google Scholar] [CrossRef]
  40. Park, S.Y.; Jin, M.L.; Yi, E.H.; Kim, Y.; Park, G. Neochlorogenic acid inhibits against LPS-activated inflammatory responses through up-regulation of Nrf2/HO-1 and involving AMPK pathway. Environ. Toxicol. Pharmacol. 2018, 62, 1–10. [Google Scholar] [CrossRef]
  41. Colombo, M.; Figueiró, F.; de Fraga Dias, A.; Teixeira, H.F.; Battastini, A.M.O.; Koester, L.S. Kaempferol-loaded mucoadhesive nanoemulsion for intranasal administration reduces glioma growth in vitro. Int. J. Pharm. 2018, 543, 214–223. [Google Scholar] [CrossRef] [PubMed]
  42. Yi, X.; Zuo, J.; Tan, C.; Xian, S.; Luo, C.; Chen, S.; Yu, L.; Luo, Y. Kaempferol, a Flavonoid Compound from Gynura Medica Induced Apoptosis and Growth Inhibition in Mcf-7 Breast Cancer Cell. Afr. J. Tradit. Complement. Altern. Med. 2016, 13, 210–215. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  43. Song, H.; Bao, J.; Wei, Y.; Chen, Y.; Mao, X.; Li, J.; Yang, Z.; Xue, Y. Kaempferol inhibits gastric cancer tumor growth: An in vitro and in vivo study. Oncol. Rep. 2015, 33, 868–874. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Qin, Y.; Cui, W.; Yang, X.; Tong, B. Kaempferol inhibits the growth and metastasis of cholangiocarcinoma in vitro and in vivo. Acta Biochim. Et Biophys. Sin. 2016, 48, 238–245. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  45. Imran, M.; Salehi, B.; Sharifi-Rad, J.; Aslam Gondal, T.; Saeed, F.; Imran, A.; Shahbaz, M.; Tsouh Fokou, P.V.; Umair Arshad, M.; Khan, H.; et al. Kaempferol: A Key Emphasis to Its Anticancer Potential. Molecules 2019, 24, 2277. [Google Scholar] [CrossRef] [Green Version]
  46. Nguyen, L.T.; Lee, Y.H.; Sharma, A.R.; Park, J.B.; Jagga, S.; Sharma, G.; Lee, S.S.; Nam, J.S. Quercetin induces apoptosis and cell cycle arrest in triple-negative breast cancer cells through modulation of Foxo3a activity. Korean J. Physiol. Pharm. 2017, 21, 205–213. [Google Scholar] [CrossRef] [Green Version]
  47. Lv, L.; Liu, C.; Chen, C.; Yu, X.; Chen, G.; Shi, Y.; Qin, F.; Ou, J.; Qiu, K.; Li, G. Quercetin and doxorubicin co-encapsulated biotin receptor-targeting nanoparticles for minimizing drug resistance in breast cancer. Oncotarget 2016, 7, 32184–32199. [Google Scholar] [CrossRef]
  48. Maurya, A.K.; Vinayak, M. Anticarcinogenic action of quercetin by downregulation of phosphatidylinositol 3-kinase (PI3K) and protein kinase C (PKC) via induction of p53 in hepatocellular carcinoma (HepG2) cell line. Mol. Biol. Rep. 2015, 42, 1419–1429. [Google Scholar] [CrossRef]
  49. Lee, H.H.; Lee, S.; Shin, Y.S.; Cho, M.; Kang, H.; Cho, H. Anti-Cancer Effect of Quercetin in Xenograft Models with EBV-Associated Human Gastric Carcinoma. Molecules 2016, 21, 1286. [Google Scholar] [CrossRef] [Green Version]
  50. Lee, J.; Lee, J.; Kim, S.J.; Kim, J.H. Quercetin-3-O-glucoside suppresses pancreatic cancer cell migration induced by tumor-deteriorated growth factors in vitro. Oncol. Rep. 2016, 35, 2473–2479. [Google Scholar] [CrossRef] [Green Version]
  51. Li, Q.; Qiu, Y.; Mao, M.; Lv, J.; Zhang, L.; Li, S.; Li, X.; Zheng, X. Antioxidant mechanism of Rutin on hypoxia-induced pulmonary arterial cell proliferation. Molecules 2014, 19, 19036–19049. [Google Scholar] [CrossRef] [PubMed]
  52. Koval’Skii, I.V.; Krasnyuk, I.I.; Krasnyuk, I.I.; Nikulina, O.I.; Belyatskaya, A.V.; Kharitonov, Y.Y.; Feldman, N.B.; Lutsenko, S.V. Mechanisms of Rutin Pharmacological Action (Review). Pharm. Chem. J. 2014, 48, 73–76. [Google Scholar] [CrossRef]
  53. Kostić, D.A.; Dimitrijević, D.S.; Stojanović, G.S.; Palić, I.R.; Đorđević, A.S.; Ickovski, J.D. Xanthine Oxidase: Isolation, Assays of Activity, and Inhibition. J. Chem. 2015, 2015, 294858. [Google Scholar] [CrossRef] [Green Version]
  54. Saleh, A.; ElFayoumi, H.M.; Youns, M.; Barakat, W. Rutin and orlistat produce antitumor effects via antioxidant and apoptotic actions. Naunyn Schmiedebergs Arch. Pharm. 2019, 392, 165–175. [Google Scholar] [CrossRef] [PubMed]
  55. Huang, H.; Chen, A.Y.; Ye, X.; Li, B.; Rojanasakul, Y.; Rankin, G.O.; Chen, Y.C. Myricetin inhibits proliferation of cisplatin-resistant cancer cells through a p53-dependent apoptotic pathway. Int. J. Oncol. 2015, 47, 1494–1502. [Google Scholar] [CrossRef] [Green Version]
  56. Zang, W.; Wang, T.; Wang, Y.; Li, M.; Xuan, X.; Ma, Y.; Du, Y.; Liu, K.; Dong, Z.; Zhao, G. Myricetin exerts anti-proliferative, anti-invasive, and pro-apoptotic effects on esophageal carcinoma EC9706 and KYSE30 cells via RSK2. Tumour. Biol. 2014, 35, 12583–12592. [Google Scholar] [CrossRef]
  57. Li, M.; Chen, J.; Yu, X.; Xu, S.; Li, D.; Zheng, Q.; Yin, Y. Myricetin Suppresses the Propagation of Hepatocellular Carcinoma via Down-Regulating Expression of YAP. Cells 2019, 8, 358. [Google Scholar] [CrossRef] [Green Version]
  58. Jiang, M.; Zhu, M.; Wang, L.; Yu, S. Anti-tumor effects and associated molecular mechanisms of myricetin. Biomed. Pharmacother. 2019, 120, 109506. [Google Scholar] [CrossRef]
  59. Urias-Lugo, D.A.; Heredia, J.B.; Muy-Rangel, M.D.; Valdez-Torres, J.B.; Serna-Saldívar, S.O.; Gutiérrez-Uribe, J.A. Anthocyanins and Phenolic Acids of Hybrid and Native Blue Maize (Zea mays L.) Extracts and Their Antiproliferative Activity in Mammary (MCF7), Liver (HepG2), Colon (Caco2 and HT29) and Prostate (PC3) Cancer Cells. Plant Foods Hum. Nutr. 2015, 70, 193–199. [Google Scholar] [CrossRef]
  60. Pyo, M.Y.; Yoon, S.J.; Yu, Y.; Park, S.; Jin, M. Cyanidin-3-glucoside suppresses Th2 cytokines and GATA-3 transcription factor in EL-4 T cells. Biosci. Biotechnol. Biochem. 2014, 78, 1037–1043. [Google Scholar] [CrossRef]
  61. Zeng, L.; Gao, J.; Zhang, R. Study on anti-tumor effect of cyanidin-3-glucoside on ovarian cancer. Zhongguo Zhong Yao Za Zhi 2012, 37, 1651–1654. [Google Scholar] [PubMed]
  62. Guo, H.; Liu, G.; Zhong, R.; Wang, Y.; Wang, D.; Xia, M. Cyanidin-3-O-beta-glucoside regulates fatty acid metabolism via an AMP-activated protein kinase-dependent signaling pathway in human HepG2 cells. Lipids Health Dis. 2012, 11, 10. [Google Scholar] [CrossRef] [Green Version]
  63. Ni, T.; Yang, W.; Xing, Y. Protective effects of delphinidin against H2O2-induced oxidative injuries in human retinal pigment epithelial cells. Biosci. Rep. 2019, 39, BSR20190689. [Google Scholar] [CrossRef] [Green Version]
  64. Lee, D.-Y.; Park, Y.-J.; Song, M.-G.; Kim, D.R.; Zada, S.; Kim, D.-H. Cytoprotective Effects of Delphinidin for Human Chondrocytes against Oxidative Stress through Activation of Autophagy. Antioxidants 2020, 9, 83. [Google Scholar] [CrossRef] [Green Version]
  65. Chamcheu, J.C.; Adhami, V.M.; Esnault, S.; Sechi, M.; Siddiqui, I.A.; Satyshur, K.A.; Syed, D.N.; Dodwad, S.M.; Chaves-Rodriquez, M.I.; Longley, B.J.; et al. Dual Inhibition of PI3K/Akt and mTOR by the Dietary Antioxidant, Delphinidin, Ameliorates Psoriatic Features In Vitro and in an Imiquimod-Induced Psoriasis-Like Disease in Mice. Antioxid. Redox Signal. 2017, 26, 49–69. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  66. Bhardwaj, P.; Khanna, D. Green tea catechins: Defensive role in cardiovascular disorders. Chin. J. Nat. Med. 2013, 11, 345–353. [Google Scholar] [CrossRef]
  67. Suzuki, J.; Ogawa, M.; Futamatsu, H.; Kosuge, H.; Sagesaka, Y.M.; Isobe, M. Tea catechins improve left ventricular dysfunction, suppress myocardial inflammation and fibrosis, and alter cytokine expression in rat autoimmune myocarditis. Eur. J. Heart Fail. 2007, 9, 152–159. [Google Scholar] [CrossRef]
  68. Cheng, A.W.; Tan, X.; Sun, J.Y.; Gu, C.M.; Liu, C.; Guo, X. Catechin attenuates TNF-alpha induced inflammatory response via AMPK-SIRT1 pathway in 3T3-L1 adipocytes. PLoS ONE 2019, 14, e0217090. [Google Scholar] [CrossRef] [Green Version]
  69. Frei, B.; Higdon, J.V. Antioxidant activity of tea polyphenols in vivo: Evidence from animal studies. J. Nutr. 2003, 133, 3275S–3284S. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  70. Bak, M.J.; Jun, M.; Jeong, W.S. Procyanidins from wild grape (Vitis amurensis) seeds regulate ARE-mediated enzyme expression via Nrf2 coupled with p38 and PI3K/Akt pathway in HepG2 cells. Int. J. Mol. Sci. 2012, 13, 801–818. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  71. Bak, M.J.; Truong, V.L.; Ko, S.Y.; Nguyen, X.N.; Ingkasupart, P.; Jun, M.; Shin, J.Y.; Jeong, W.S. Antioxidant and Hepatoprotective Effects of Procyanidins from Wild Grape (Vitis amurensis) Seeds in Ethanol-Induced Cells and Rats. Int. J. Mol. Sci. 2016, 17, 758. [Google Scholar] [CrossRef] [PubMed]
  72. Chu, H.; Tang, Q.; Huang, H.; Hao, W.; Wei, X. Grape-seed proanthocyanidins inhibit the lipopolysaccharide-induced inflammatory mediator expression in RAW264.7 macrophages by suppressing MAPK and NF-kappab signal pathways. Env. Toxicol. Pharm. 2016, 41, 159–166. [Google Scholar] [CrossRef] [PubMed]
  73. Limtrakul, P.; Yodkeeree, S.; Pitchakarn, P.; Punfa, W. Anti-inflammatory effects of proanthocyanidin-rich red rice extract via suppression of MAPK, AP-1 and NF-κB pathways in Raw 264.7 macrophages. Nutr. Res. Pract. 2016, 10, 251. [Google Scholar] [CrossRef] [Green Version]
  74. Cho, B.O.; Yin, H.H.; Park, S.H.; Byun, E.B.; Ha, H.Y.; Jang, S.I. Anti-inflammatory activity of myricetin from Diospyros lotus through suppression of NF-κB and STAT1 activation and Nrf2-mediated HO-1 induction in lipopolysaccharide-stimulated RAW264.7 macrophages. Biosci. Biotechnol. Biochem. 2016, 80, 1520–1530. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  75. Liao, H.-H.; Zhu, J.-X.; Feng, H.; Ni, J.; Zhang, N.; Chen, S.; Liu, H.-J.; Yang, Z.; Deng, W.; Tang, Q.-Z. Myricetin Possesses Potential Protective Effects on Diabetic Cardiomyopathy through Inhibiting IκBα/NFκB and Enhancing Nrf2/HO-1. Oxidative Med. Cell. Longev. 2017, 2017, 1–14. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  76. Kadioglu, O.; Nass, J.; Saeed, M.E.; Schuler, B.; Efferth, T. Kaempferol Is an Anti-Inflammatory Compound with Activity towards NF-κB Pathway Proteins. Anticancer Res. 2015, 35, 2645–2650. [Google Scholar] [PubMed]
  77. Sun, Z.; Li, Q.; Hou, R.; Sun, H.; Tang, Q.; Wang, H.; Hao, Z.; Kang, S.; Xu, T.; Wu, S. Kaempferol-3-O-glucorhamnoside inhibits inflammatory responses via MAPK and NF-kappaB pathways in vitro and in vivo. Toxicol. Appl. Pharm. 2019, 364, 22–28. [Google Scholar] [CrossRef] [PubMed]
  78. Das, N.; Sikder, K.; Bhattacharjee, S.; Majumdar, S.B.; Ghosh, S.; Majumdar, S.; Dey, S. Quercetin alleviates inflammation after short-term treatment in high-fat-fed mice. Food Funct. 2013, 4, 889–898. [Google Scholar] [CrossRef] [PubMed]
  79. Noh, H.J.; Kim, C.S.; Kang, J.H.; Park, J.Y.; Choe, S.Y.; Hong, S.M.; Yoo, H.; Park, T.; Yu, R. Quercetin suppresses MIP-1alpha-induced adipose inflammation by downregulating its receptors CCR1/CCR5 and inhibiting inflammatory signaling. J. Med. Food 2014, 17, 550–557. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  80. Hämäläinen, M.; Nieminen, R.; Vuorela, P.; Heinonen, M.; Moilanen, E. Anti-inflammatory effects of flavonoids: Genistein, kaempferol, quercetin, and daidzein inhibit STAT-1 and NF-kappaB activations, whereas flavone, isorhamnetin, naringenin, and pelargonidin inhibit only NF-kappaB activation along with their inhibitory effect on iNOS expression and NO production in activated macrophages. Mediat. Inflamm. 2007, 2007, 45673. [Google Scholar] [CrossRef] [Green Version]
  81. Chang, Y.C.; Tsai, M.H.; Sheu, W.H.; Hsieh, S.C.; Chiang, A.N. The therapeutic potential and mechanisms of action of quercetin in relation to lipopolysaccharide-induced sepsis in vitro and in vivo. PLoS ONE 2013, 8, e80744. [Google Scholar] [CrossRef] [PubMed]
  82. Napimoga, M.H.; Clemente-Napimoga, J.T.; Macedo, C.G.; Freitas, F.F.; Stipp, R.N.; Pinho-Ribeiro, F.A.; Casagrande, R.; Verri, W.A., Jr. Quercetin inhibits inflammatory bone resorption in a mouse periodontitis model. J. Nat. Prod. 2013, 76, 2316–2321. [Google Scholar] [CrossRef] [PubMed]
  83. Xia, Y.; Shen, S.; Verma, I.M. NF-κB, an active player in human cancers. Cancer Immunol. Res. 2014, 2, 823–830. [Google Scholar] [CrossRef] [Green Version]
  84. Zhang, W.; Li, B.; Guo, Y.; Bai, Y.; Wang, T.; Fu, K.; Sun, G. Rhamnetin attenuates cognitive deficit and inhibits hippocampal inflammatory response and oxidative stress in rats with traumatic brain injury. Cent. Eur. J. Immunol. 2015, 40, 35–41. [Google Scholar] [CrossRef] [Green Version]
  85. Hirai, S.; Kim, Y.I.; Goto, T.; Kang, M.S.; Yoshimura, M.; Obata, A.; Yu, R.; Kawada, T. Inhibitory effect of naringenin chalcone on inflammatory changes in the interaction between adipocytes and macrophages. Life Sci. 2007, 81, 1272–1279. [Google Scholar] [CrossRef]
  86. Rammohan, A.; Reddy, J.S.; Sravya, G.; Rao, C.N.; Zyryanov, G.V. Chalcone synthesis, properties and medicinal applications: A review. Environ. Chem. Lett. 2020, 18, 433–458. [Google Scholar] [CrossRef]
  87. Rasul, A.; Millimouno, F.M.; Ali Eltayb, W.; Ali, M.; Li, J.; Li, X. Pinocembrin: A novel natural compound with versatile pharmacological and biological activities. BioMed Res. Int. 2013, 2013, 379850. [Google Scholar] [CrossRef]
  88. Gagliotti Vigil de Mello, S.V.; Frode, T.S. In Vitro and In Vivo Experimental Model-based Approaches for Investigating Anti-inflammatory Properties of Coumarins. Curr. Med. Chem. 2018, 25, 1446–1476. [Google Scholar] [CrossRef]
  89. Shin, S.Y.; Yoon, H.; Ahn, S.; Kim, D.W.; Bae, D.H.; Koh, D.; Lee, Y.H.; Lim, Y. Structural properties of polyphenols causing cell cycle arrest at G1 phase in HCT116 human colorectal cancer cell lines. Int. J. Mol. Sci. 2013, 14, 16970–16985. [Google Scholar] [CrossRef] [Green Version]
  90. Feng, R.; Lu, Y.; Bowman, L.L.; Qian, Y.; Castranova, V.; Ding, M. Inhibition of activator protein-1, NF-kappaB, and MAPKs and induction of phase 2 detoxifying enzyme activity by chlorogenic acid. J. Biol. Chem. 2005, 280, 27888–27895. [Google Scholar] [CrossRef] [Green Version]
  91. Granado-Serrano, A.B.; Angeles Martín, M.; Goya, L.; Bravo, L.; Ramos, S. Time-course regulation of survival pathways by epicatechin on HepG2 cells. J. Nutr. Biochem. 2009, 20, 115–124. [Google Scholar] [CrossRef] [PubMed]
  92. Malik, S.A.; Acharya, J.D.; Mehendale, N.K.; Kamat, S.S.; Ghaskadbi, S.S. Pterostilbene reverses palmitic acid mediated insulin resistance in HepG2 cells by reducing oxidative stress and triglyceride accumulation. Free Radic. Res. 2019, 53, 815–827. [Google Scholar] [CrossRef] [PubMed]
  93. Cioffi, G.; Morales Escobar, L.; Braca, A.; De Tommasi, N. Antioxidant chalcone glycosides and flavanones from Maclura (Chlorophora) tinctoria. J. Nat. Prod. 2003, 66, 1061–1064. [Google Scholar] [CrossRef] [PubMed]
Pharmaceuticals 15 01231 g001 550
Figure 1. Flowchart summarizing the literature selection process according to PRISMA methodology.
Figure 1. Flowchart summarizing the literature selection process according to PRISMA methodology.
Pharmaceuticals 15 01231 g001
Pharmaceuticals 15 01231 g002 550
Figure 2. Structure of identified chalcones in C. album: (A) R = OH, 2′,4′-dihydroxydihydrochalcone, R = OCH3, 2′-methoxy-4′-hydroxydihydrochalcone; (B) 2′,4′-dihydroxychalcone.
Figure 2. Structure of identified chalcones in C. album: (A) R = OH, 2′,4′-dihydroxydihydrochalcone, R = OCH3, 2′-methoxy-4′-hydroxydihydrochalcone; (B) 2′,4′-dihydroxychalcone.
Pharmaceuticals 15 01231 g002
Pharmaceuticals 15 01231 g003 550
Figure 3. Summary of bioactive properties found in the literature for C. album berries, leaves, or their extracts.
Figure 3. Summary of bioactive properties found in the literature for C. album berries, leaves, or their extracts.
Pharmaceuticals 15 01231 g003
Table
Table 1. Phenolic compounds identified in C. album Berries.
Table 1. Phenolic compounds identified in C. album Berries.
GroupSub-GroupCompoundGeneral StructureRef.
PHENOLIC ACIDS Benzoic acidPharmaceuticals 15 01231 i001[12]
Salicilic acidPharmaceuticals 15 01231 i002[12]
Tannic acidPharmaceuticals 15 01231 i003[13]
Hydroxibenzoic acidsp-hydroxybenzoic acid (R=R1=R2=H) and derivatives
Vanillic acid (R=R1=H; R2=OCH3)
Protocatechuic acid (R=R1=H; R2=OH)
Syringic aid (R=H; R1=R2= OCH3)
Gallic acid (R=H; R1=R2=OH) 		Pharmaceuticals 15 01231 i004[7,10,11,12,14]
Hydroxicinnamic acidst-Cinnamic acid Pharmaceuticals 15 01231 i005[12]
p-coumaric acid (R=R1=R2=H)
Sinapic acid (R=H; R1=R2=OCH3)
Ferulic acid (R=R2=H; R1=OCH3) and derivatives
Caffeic acid and derivatives (R=R2=H; R1=OH/O-Hexose; R2=H)		Pharmaceuticals 15 01231 i006[7,12,14]
Chlorogenic acid (R=R1=R2=H; R3=Caffeic acid)
Neochlorogenic acid (R=R1=R2= H; R3= Caffeic acid)
Cryptochlorogenic acid (R=R2=R4=H; R3= Caffeic acid)		Pharmaceuticals 15 01231 i007[7,14,15,16]
FLAVONOIDSFlavonolsKaempherol (R1=R2=R4=OH; R3=R5=R6=H) and derivatives:
- i.e., Kaempherol 3-O-galactoside (R6=galactose)
- i.e., Kaempherol 3-O-glucoside (R6=glucose)		Pharmaceuticals 15 01231 i008[7,14,15,16]
Quercetin (R=R1=R2=R3=OH; R4=R5=H) and derivatives:
- i.e., Quercetin 3-O-glucoside (R5=glucose)
- i.e., Quercetin 3-O-arabinoside (R5=arabinose)
- i.e., Quercetin 3-O-galactoside (R5=galactose)
- i.e., Quercetin rhamnoside (R5=rhamnose)
Rutin (R= R1= R2=R3=OH; R4=H; R5=glucopyranose)		[7,15,16]
Myricetin (R=R1=R2=R3=OH; R4=H; R5=OH) and derivatives:
- i.e., Myricetin 3-O-glucoside (R=R1=R2=R3=OH; R4=H; R5=O-glucose)		[7,15,16]
Catechin (R=R1=R2=R3=R4=R5=OH) and derivatives[15]
Procyanidin (R=H, n=1) and derivatives:
- i.e., Procyanidin Dimer type A (R=H, n=2)		Pharmaceuticals 15 01231 i009[15]
FlavanonespinocembrinPharmaceuticals 15 01231 i010[7]
6-geranylnaringeninPharmaceuticals 15 01231 i011[7]
AnthocyaninsCyanidin (R1=R2=OH; R3=R4=R5=R6=H) and derivatives
- i.e., Cyanidin 3-O-glucoside (R6=glucose)
- i.e., Cyanidin 3-O-arabinoside (R6=arabinose)		Pharmaceuticals 15 01231 i012[7]
Delphinidin (R1=R2=R3=R4=R5=OH; R6=H) and derivatives:
- i.e., Delphinidin 3-O-glucoside (R6= glucose)		[7]
STILBENES Resveratrol (R1=R2=H) and derivatives:
- i.e., Pterostilbene (R1=R2=CH3)
- i.e., Stilbene Hexoside (R2=Hexose)		Pharmaceuticals 15 01231 i013[7,15]
Table
Table 2. Phenolic compounds identified in C. album leaves.
Table 2. Phenolic compounds identified in C. album leaves.
GroupSub-GroupCompoundGeneral StructureRef.
PHENOLIC ACIDSHydroxycinnamic acidsCoumaric acid (R=R1=R2=H) and derivatives:
- i.e., Coumaroyl Glucose (R=Glucose)		Pharmaceuticals 15 01231 i014[15,16]
FLAVONOIDSFlavanolsCatechin (R=R1=R2=R3=R4=R5=OH) and derivatives:
- i.e., Catechin 3-O-glucose (R3=Glucose)
Epicatechin (R=R1=R2=R5=OH; R3=R4=H)		Pharmaceuticals 15 01231 i015[15,16]
Procyanidin (R=H, n=1) and derivatives:
- i.e., Procyanidin Trimer (R=H, n=3)
- i.e., Procyanidin Tretramer (R=H, n=4)
- i.e., Procyanidin Galhate (R=Galhate, n=1)		Pharmaceuticals 15 01231 i016[15,16]
Flavones or FlavonolsMyricetin (R=R1=R2=R3=R5=OH; R4=H) and derivatives:
- i.e., Myricetin 3-O-galactoside (R5=O-galactose)
- i.e., Myricetin 3-O-glucoside (R5=O-glucose)
- i.e., Myricetin Xyloside (R5=O-xylose)
- i.e., Myricetin Rhamnoside (R5=O-rhamnose)
- i.e., Myricetin Methyl ether Hexoside 		Pharmaceuticals 15 01231 i017[15,16]
Kaempherol (R=R1=R3=OH; R2=R4=R5=H) and derivatives:
- i.e., Kaempherol Hexoside (R5=Hexose)		Pharmaceuticals 15 01231 i018[15]
Rhamnetin (R=OCH3; R1=R2=R3=OH; R4=R5=H) and derivatives:
- i.e., Rhamnetin Hexoside (R5=Hexose)		[16]
Quercetin (R=R1=R2=R3=OH; R4=R5=H) and derivatives:
- i.e., Quercitin-3-O-glucoside (R5=glucose)
- i.e., Quercitin-3-O-galactoside (R5=galactose)
- i.e., Quercetin Rhamnosyl Hexoside (R5=Rhamnosoyl Hexose)
- i.e., Methyl-quercitin hexoside (R5=Hexose)
Rutin (R= R1= R2=R3=OH; R4=H; R5=glucopyranose)		[15,16]
PinocembrinPharmaceuticals 15 01231 i019[18]
STILBENES Stilbenes and derivativesPharmaceuticals 15 01231 i020[15,16]
Table
Table 3. Protective mechanisms ascribed to phenolic compounds identified in C. album berries.
Table 3. Protective mechanisms ascribed to phenolic compounds identified in C. album berries.
CompoundProtective Mechanisms (s)Experimental ModelRef.
p-hydroxybenzoic acid
  • Inhibits iNOS/NO and COX-2/PGE2 production.
  • Suppresses MAPKs, IKK, IkB, and p65 phosphorylation; and p65 nuclear translocation.
  • Inhibits IL-1β, IL-6, and TNF-α production.
  • Downregulates iNOS and COX-2 expression.
Mouse macrophages[24]
p-coumaric acid
  • Suppresses apoptosis via modulation of MAPK signalling pathway.
  • Suppresses IL-6 and TNF-α levels
- Human epithelial cells
- Animal models: rheumatoid arthritis rats		[25,26]
Ferulic acid
  • Reduces UV-B radiation-induced oxidation.
  • Suppresses NF-κB and MAPK pathways.
  • Inhibits H2O2-induced MAPK activation via ROS pathway
- Human lymphocytes
- Bovine endometrial epithelial cells
- Rat vascular smooth muscle cells		[27,28,29]
Caffeic acid and derivatives
  • Reduces mRNA and protein synthesis of TNF-α, IL-6, IL-1β cytokines.
  • Induces apoptosis.
- Human cancer cells fibrosarcoma
- Animal model: albino mice (BALB/c)		[30,31]
Chlorogenic acid
  • Downregulates LPS-induced COX-2 up-expression.
  • Inhibits PGE2, NF-κB, JNK/AP-1 signalling pathway activation.
  • Inhibits production of TNF-α, IL-6, IL-1β, IFN-γ, MIP-1α.
- Mouse macrophages[32,33,34,35,36]
Neochlorogenic acid
  • Reduces production of TNF-α, IL-1β, IL-6 and NO.
  • Inhibits NF-κB activation and blocks MAPK signalling pathway phosphorylation.
  • Increases HO-1 expression via AMPK/Nrf2 signalling pathway activation.
  • Reduces CM-activated IκB/NFκB, STAT3 expression, and Akt/mTOR pathways.
- Human cancer cells: lung
- Mouse cells: macrophages, microglia, fibroblasts		[37,38,39,40]
Kaempherol and derivatives
  • Upregulates caspase-3 activity.
  • Induces apoptosis.
  • Inhibits cell growth.
  • Induces Cell-cycle arrest at G2/M
- Human cancer cells: brain, breast, stomach, liver, QBC939 (human cholangiocarcinoma)
- HCCC9810 (mice) and (human) 		[41,42,43,44,45]
Quercetin and derivatives
Rutin
  • Increases apoptosis.
  • Inhibits cell cycle progression.
  • Inhibits P-glycoprotein expression.
  • Upregulates p53 and BAX expression.
  • Downregulates PI3K, PKC, COX-2 and ROS expression.
  • Downregulates hypoxia-induced Nox4.
  • Inhibits xanthine oxidase.
  • Inhibits lipid peroxidation.
  • Induces G2/M cell cycle arrest.
  • Increases apoptosis.
- Human cancer cells: breast, liver
- Human cancer cells: neuroblastoma
- Animal models: Calf lung and muscle cells;
Albino rats of Wistar strain.		[46,47,48,49,50]
[51,52,53,54]
Myricetin and derivatives
  • Increases apoptosis through reduction in Bcl-2 and pro-caspase-3 levels and increase in BAX and cleaved caspase-3 levels.
  • Decreases cell proliferation through stimulation of phosphorylation and degradation of YAP.
  • Increases cell cycle arrest.
  • Reduces metastasis.
- Human cancer cells: esophagus, ovary, and liver[55,56,57,58]
Cyanidin and derivatives
  • Reduces cell proliferation.
  • Reduces IL-3 and IL-4 by GATA-3 inhibition.
  • Increases apoptosis.
  • Decreases mucin 4 expression.
  • Increases fatty acid oxidation and AMPK activity.
- Human cancer cells: breast, liver, colon, prostate and ovarian.
- Animal model:
Murine thymoma		[59,60,61,62]
Delphinidin and derivatives
  • Inhibits BAX and caspase 3.
  • Increases Bcl-2 protein.
  • Inhibits intracellular ROS generation and Nox1 protein.
  • Normalizes the enzyme activity of SOD, CAT, GSH-PX and MDA levels via increase in nuclear Nrf2 protein.
  • Increases NF-κB and Nrf2 pathways antioxidant response.
  • Inhibits activation of PI3K/Akt/mTOR components and secretion of proinflammatory cytokines and chemokines.
- Human cells (normal): eye, keratinocytes
- Transformed cell line: human chondrocyte		[63,64,65]
Abbreviations: AKT—Protein kinase B; AP-1—Activator protein 1; BAX—Bcl-2-like protein 4; Bcl-2—B-cell lymphoma-2; CAT—Catalase; CM—conditioned medium; COX-2—Cyclooxygease-2; GSH-PX—Glutathione peroxidase; H2O2—hydrogen peroxide; HO-1—Heme oxygenase 1; IFN-γ—Interferon γ; IL—Interleukin; iNOS—Inducible nitric oxide synthase; IκB—NF-κB inhibitor; IKK—IκB kinase; JNK—c-Jun N-terminal kinase; lncRNA-MALAT1—Long non-coding RNAs of metastasis associated lung adenocarcinoma transcript 1; LPS—Lipopolysaccharide; MAPK—Mitogen-activated protein kinase; MDA—Malondialdehyde; MIP-1α—Macrophage inflammatory protein-1; mRNA—messenger RNA (ribonucleic acid); mTOR—mammalian target of rapamycin; NF-κB—Nuclear factor kappa-light-chain-enhancer of activated B-cell; NO—Nitric oxide; Nox1—NADPH (nicotinamide adenine dinucleotide phosphate) oxidase 1; Nox4—NADPH (nicotinamide adenine dinucleotide phosphate) oxidase 4; Nrf2—Nuclear factor erythroid factor 2-related factor 2; p53—Tumor protein p53; p65—Nuclear translocation of p65 subunit of NF-κB and NF-κB DNA binding activity; PGE2—Prostaglandin E2; PI3K—Phosphatidylinositol-3-kinase; PKC—Protein kinase C; ROS—Reactive oxygen species; SOD—Superoxide dismutase; STAT3—Signal transducer and activator of transcription 3; TNF-α—Tumor necrosis factor α; UV-B—Ultraviolet B; YAP—Yes-associated protein.
Table
Table 4. Protective mechanisms ascribed to phenolic compounds identified in C. album leaves.
Table 4. Protective mechanisms ascribed to phenolic compounds identified in C. album leaves.
CompoundProtective Mechanisms (s)Experimental ModelRef.
Catechin and derivatives
Epicatechin
  • Inhibits NF-κB and AP-1.
  • Inhibits “pro-oxidant” enzymes and induces antioxidant enzymes.
  • Suppresses inflammatory factors including NF-κB, cytokines and adhesion molecules.
  • Reduces IL-6, IL-12, IL-1α and IL-1β mRNA expression induced by TNF-α.
- Animal studies: mice and rats.
- Animal model: experimental autoimmune myocarditis rats, mouse fibroblasts		[66,67,68,69]
Procyanidin and derivatives
  • Upregulates expression and activity of antioxidant enzymes via ERK, JNK and p38 MAPK pathways.
  • Upregulates Nfr2 expression and activates Nfr2 antioxidant response element-mediated transcription via p38 MAPK and PI3K/Akt pathways.
  • Downregulates mRNA expression of proinflammatory cytokines such as TNF-α, IL-1β and inflammatory molecules of COX-2.
  • Upregulates mRNA expression of IL-10
  • Suppresses MAPK, AP-1 and NF-κB pathways.
- Human cancer cells: liver
- Animal models: Rat liver, mouse macrophages		[70,71,72,73]
Myricetin and derivatives
  • Inhibits production of pro-inflammatory mediators (NO, iNOS, PGE2, and COX-2).
  • Decreases NO, iNOS, TNF-α, IL-6 and IL-12 production.
  • Decreases NF-κB activation (suppresses degradation of IκBα, nuclear translocation of p65 subunit of NF-κB and NF-κB DNA-binding activity).
  • Attenuates phosphorylation of STAT1 and IFN-β production.
  • Upregulates HO-1 expression through Nrf2 translocation.
- Animal model: mouse macrophage, diabetic cardiomyopathy mice[74,75]
Kaempherol and derivatives
  • Suppresses NF-κB pathway by targeting protein-docking sites.
  • Modulates expression of inflammatory cytokines (TNF-α, IL-6, IL-1β and PGE2).
  • Modulates phosphorylation of IκBα and p65.
  • Inhibits phosphorylation of p38, ERK and JNK
- Human cancer cells: leukemia
Animal model: mouse macrophage		[76,77]
Quercetin and derivatives
  • Downregulates the expressions of iNOS and IFN-γ
  • Attenuates NF-κB-mediated inflammation. (Scavenges ROS, necessary for NF-κB activation, or blocks TNF-α-dependent commencement of nuclear translocation of NF-κB)
  • Suppresses MIP-1α-mediated migration/activation of macrophages through downregulation of CCR1/CCR5 production and inhibition of inflammatory signalling activation in macrophages.
  • Inhibits MAPKs (ERK and JNK) and transcription factors (NF-κB and AP-1).
  • Downregulates mRNA and protein levels of TNF-α, IL-1β, IL-6, iNOS and MIP-1α
  • Downregulates microRNA 155 levels, inhibiting NF-κB activation.
  • Reduces IL-1β, TNF-α, IL-17 and intercellular adhesion molecule 1 production
- Animal model:
HFD-induced inflammatory mice, mouse macrophages, male C57BL/6 mice, periodontitis mice		[78,79,80,81,82]
Abbreviations: AKT—Protein kinase B; AP-1—Activator protein 1; CCR1—C-C chemokine receptor type 1; CCR5—C-C chemokine receptor type 5; COX-2—Cyclooxygease-2; ERK—Extracellular signal-regulated kinase; HO-1—Heme oxygenase 1; IFN-β—Interferon β; IFN-γ—Interferon γ; IL—Interleukin; iNOS—Inducible nitric oxide synthase; IκBα—NF-κB inhibitor α; IκB—NF-κB inhibitor; JNK—c-Jun N-terminal kinase; MAPK—Mitogen-activated protein kinase; MIP-1α—Macrophage inflammatory protein-1; mRNA—messenger RNA (ribonucleic acid); NF-κB—Nuclear factor kappa-light-chain-enhancer of activated B-cell; NO—Nitric oxide; Nrf2—Nuclear factor erythroid factor 2-related factor 2; p65—Nuclear translocation of p65 subunit of NF-κB and NF-κB DNA binding activity; PGE2—Prostaglandin E2; PI3K—Phosphatidylinositol-3-kinase; ROS—Reactive oxygen species; STAT1—Signal transducer and activator of transcription 1; TNF-α—Tumor necrosis factor α.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Cerquido, A.S.; Vojtek, M.; Ribeiro-Oliveira, R.; Viegas, O.; Sousa, J.B.; Ferreira, I.M.P.L.V.O.; Diniz, C. Unravelling Potential Health-Beneficial Properties of Corema album Phenolic Compounds: A Systematic Review. Pharmaceuticals 2022, 15, 1231. https://doi.org/10.3390/ph15101231

AMA Style

Cerquido AS, Vojtek M, Ribeiro-Oliveira R, Viegas O, Sousa JB, Ferreira IMPLVO, Diniz C. Unravelling Potential Health-Beneficial Properties of Corema album Phenolic Compounds: A Systematic Review. Pharmaceuticals. 2022; 15(10):1231. https://doi.org/10.3390/ph15101231

Chicago/Turabian Style

Cerquido, Ana Sofia, Martin Vojtek, Rita Ribeiro-Oliveira, Olga Viegas, Joana Beatriz Sousa, Isabel M. P. L. V. O. Ferreira, and Carmen Diniz. 2022. "Unravelling Potential Health-Beneficial Properties of Corema album Phenolic Compounds: A Systematic Review" Pharmaceuticals 15, no. 10: 1231. https://doi.org/10.3390/ph15101231

APA Style

Cerquido, A. S., Vojtek, M., Ribeiro-Oliveira, R., Viegas, O., Sousa, J. B., Ferreira, I. M. P. L. V. O., & Diniz, C. (2022). Unravelling Potential Health-Beneficial Properties of Corema album Phenolic Compounds: A Systematic Review. Pharmaceuticals, 15(10), 1231. https://doi.org/10.3390/ph15101231

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop